CDC Releases Additional Doses of Nirsevimab-Alip for RSV Imm

More than 77,000 additional doses of nirsevimab-alip will be distributed for respiratory syndactyl virus (RSV) immunization in infants.

Related Keywords

United States , Alaska , American , Niravd Shah , Patrizia Cavazzoni , American College Of Obstetricians , American College , American Indian , Alaska Native , Drug Evaluation , Rsv Vaccines , Fda Approval , Nirsevimab , Beyfortus , Rsv Vaccines For Infants ,